Interpace Diagnostics Group (IDXG) Earns Daily Media Impact Rating of 0.06
News articles about Interpace Diagnostics Group (NASDAQ:IDXG) have trended somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Interpace Diagnostics Group earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave headlines about the business services provider an impact score of 45.057659873108 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Bombardier jobs hugely important to N. Ireland – PM May’s spokesman (feeds.reuters.com)
- BRIEF-Interpace Diagnostics Group Inc – assigned a new, discreet CPT code to facilitate reimbursement of Thyramir (reuters.com)
- Interpace Diagnostics (IDXG) Reports New CPT Code for Reimbursement of Molecular Thyroid Test (streetinsider.com)
- ValuEngine Upgrades Interpace Diagnostics Group, Inc. (IDXG) to “Sell” (americanbankingnews.com)
- Interpace Diagnostics Announces New CPT Code for Reimbursement of Molecular Thyroid Test (finance.yahoo.com)
Shares of Interpace Diagnostics Group (NASDAQ IDXG) opened at 1.38 on Thursday. Interpace Diagnostics Group has a 52 week low of $0.07 and a 52 week high of $14.25. The firm’s 50-day moving average price is $1.19 and its 200 day moving average price is $1.76. The stock’s market capitalization is $30.58 million.
Interpace Diagnostics Group (NASDAQ:IDXG) last issued its quarterly earnings data on Thursday, August 10th. The business services provider reported ($0.65) EPS for the quarter. The business had revenue of $3.86 million during the quarter. Interpace Diagnostics Group had a negative return on equity of 32.06% and a negative net margin of 37.08%.
Several research firms recently weighed in on IDXG. ValuEngine upgraded Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a research note on Monday. Maxim Group assumed coverage on Interpace Diagnostics Group in a research note on Tuesday, August 15th. They set a “buy” rating and a $5.00 target price on the stock.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/14/interpace-diagnostics-group-idxg-earns-daily-media-impact-rating-of-0-06.html.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.
Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.